About Collagenase 3
Collagenase 3 (MMP13) is a protein
from Homo sapiens identified by UniProt accession
P45452, 471 residues long.
MolForge cross-references it against 0 known binders and
696 disease associations.
Target properties
| Protein name | Collagenase 3 |
| UniProt accession | P45452 |
| Gene | MMP13 |
| Organism | Homo sapiens |
| Length | 471 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (696)
Diseases linked to this target (Open Targets).
- spondyloepimetaphyseal dysplasia, Missouri type · score 0.79
- metaphyseal chondrodysplasia, Spahr type · score 0.68
- acne · score 0.61
- rosacea · score 0.59
- periodontitis · score 0.59
- Helicobacter pylori infectious disease · score 0.59
- infection · score 0.58
- COVID-19 · score 0.58
- Lyme disease · score 0.57
- Borrelia infectious disease · score 0.56
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P45452-F1 | alphafold | PREDICTED | 88.60 | — |
Amino-acid sequence (471 residues)
MHPGVLAAFL FLSWTHCRAL PLPSGGDEDD LSEEDLQFAE RYLRSYYHPT NLAGILKENA ASSMTERLRE MQSFFGLEVT GKLDDNTLDV MKKPRCGVPD VGEYNVFPRT LKWSKMNLTY RIVNYTPDMT HSEVEKAFKK AFKVWSDVTP LNFTRLHDGI ADIMISFGIK EHGDFYPFDG PSGLLAHAFP PGPNYGGDAH FDDDETWTSS SKGYNLFLVA AHEFGHSLGL DHSKDPGALM FPIYTYTGKS HFMLPDDDVQ GIQSLYGPGD EDPNPKHPKT PDKCDPSLSL DAITSLRGET MIFKDRFFWR LHPQQVDAEL FLTKSFWPEL PNRIDAAYEH PSHDLIFIFR GRKFWALNGY DILEGYPKKI SELGLPKEVK KISAAVHFED TGKTLLFSGN QVWRYDDTNH IMDKDYPRLI EEDFPGIGDK VDAVYEKNGY IYFFNGPIQF EYSIWSNRIV RVMPANSILW C
Explore Collagenase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets